Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 17Unknown 8Recruiting 8Active not recruiting 5Terminated 4Not yet recruiting 2Withdrawn 1Enrolling by invitation 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 5Triple Negative Breast Neoplasms 1Cystic Fibrosis 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Paclitaxel 62Letrozole 55Fulvestrant 55Trastuzumab 50palbociclib 41pembrolizumab 37Cyclophosphamide 37Carboplatin 37Anastrozole 37pertuzumab 35exemestane 25Tamoxifen 24Capecitabine 24ribociclib 23abemaciclib 23Radiotherapy 21Docetaxel 21olaparib 20Doxorubicin 20Magnetic Resonance Spectroscopy 19trastuzumab deruxtecan 17Surveys and Questionnaires 17durvalumab 16Epirubicin 16Specimen Handling 14Exercise 14130-nm albumin-bound paclitaxel 14Taxes 13Alpelisib 13Goserelin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Breast Neoplasms × Mastectomy × Clear all
NCT02883062 2026-05-28

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
67 enrolled 16 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02326974 2026-04-17

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
164 enrolled 19 charts
Breast

Breast Neoplasms

NCT02624973 2026-02-12

PETREMAC

Haukeland University Hospital

Phase 2 Active not recruiting
200 enrolled
Breast

Breast Neoplasms

NCT04585074 2025-05-15

MARRES

Severance Hospital

Active not recruiting
2,000 enrolled
Breast

Breast Neoplasms, Cystic Fibrosis

NCT06378294 2025-03-20

MACMA

University Hospital A Coruña

Active not recruiting
82 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡